Alzheimers disease: A review of recent developments

Annals of African Medicine

Volumn 10, Issue 2, 2011, Pages 73-79

  Salawu, Fatai K ^a   Umar, Joel T ^b   Olokoba, Abdulfatai B ^c  

^a FEDERAL MEDICAL CENTER   (Nigeria)

^b Specialist Hospital Yola Nigeria   (Nigeria)

^c UNIVERSITY OF ILORIN   (Nigeria)

Author keywords

Advancing age; Alzheimers disease; cognitive dysfunction; dementia; neuropsychological testing; primary neuronal degeneration

Indexed keywords

ALPHA TOCOPHEROL; ALPRAZOLAM; AMYLOID BETA PROTEIN; ANTIDEPRESSANT AGENT; ANTIOXIDANT; APOLIPOPROTEIN E; BENZODIAZEPINE DERIVATIVE; BETA SECRETASE INHIBITOR; CARBON 11; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; FLAVONOID GLYCOSIDE; FLUORODEOXYGLUCOSE F 18; GALANTAMINE; GAMMA SECRETASE INHIBITOR; GINKGO BILOBA EXTRACT; MEMANTINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; ANTIPARKINSON AGENT;

ACTIVE IMMUNIZATION; AGING; ALZHEIMER DISEASE; AMNESIA; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN FUNCTION; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; COGNITION; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ENCEPHALITIS; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; GENETIC ANALYSIS; GINKGO BILOBA; HERBAL MEDICINE; HUMAN; INSOMNIA; LOW DRUG DOSE; MEDLINE; MENTAL DISEASE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NERVE CELL DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PUBLICATION; REVIEW; RISK FACTOR; SENILE PLAQUE; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; COGNITIVE DEFECT; DISEASE COURSE; PSYCHOLOGICAL ASPECT;

AGING; ALZHEIMER DISEASE; ANTIPARKINSON AGENTS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; MEMANTINE; NEUROPSYCHOLOGICAL TESTS;

EID: 79960028128     PISSN: 15963519     EISSN: 09755764     Source Type: Journal    
DOI: 10.4103/1596-3519.82057     Document Type: Review

References (54)

1. Wilkins RH, Brody IA. Alzheimers disease. Arch Neurol 1969;21:109-10.
2. Alzheimers association. Alzheimers Disease Facts and Figures- Executive Summary. Chicago, IL, 2009.
3. Bird TD, Miller BL. Dementia. In: Fauci AS, Baunwauld E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J, editors. Harrisons Principles of Internal Medicine. 17th ed, Columbus, OH: McGraw-Hill; 2007. p. 2536-49.
4. Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex and the incidence of dementia and Alzheimers disease: A meta-analysis. Arch Gen Psychiatry 1998;55:809-15. (Pubitemid 28413043)
5. Duijn VC, Clayton D, Chandra V, Fratiglioni L, Graves AB, Heyman A, et al. Familial aggregation of Alzheimers disease and related disorders: A collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991;20: S13-20.
6. Brunkan AL, Goate AM. Presenilin function and gamma secretase activity. J Neurochem 2005;93:769-92. (Pubitemid 40695738)
7. Goedert M, Spillantini MG. A century of Alzheimers disease. Science 2006;314:777-81.
8. Scheuner D, Eckman C, Jensen M, Song X, citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimers disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimers disease. Nat Med 1996;2:864-70. (Pubitemid 26296755)
9. Tsai MS, Tangalos EG, Petersen RC, Smith GE, Schaid DJ, Kokmen E, et al. Apolipoprotein E: Risk factor for Alzheimer disease. Am J Hum Genet 1994;54:643-9. (Pubitemid 24089603)
10. Hendrie HC, Hall KS, Hui S, Unverzagt FW, Yu CE, Lahiri DK, et al. Apolipoprotein E genotypes and Alzheimers disease in a community of elderly African Americans. Ann Neurol 1995;37:118-20.
11. Osuntokun BO, Sahota A, Ogunniyi A, Gureje O, Baiyewu O, Adeyinka A, et al. Lack of association between apolipoprotein E e4 and Alzheimers disease in elderly Nigerians. Ann Neurol 1995;38:463-5.
12. Sahota A, Yang M, Gao S, Hui SL, Baiyewu O, Gureje O, et al. Apolioprotein E-associated risk for Alzheimers disease in the African-American population is genotype dependent. Ann Neurol 1997;42:659-61. (Pubitemid 27439030)
13. Rapp SR, Espeland MA, Shumaker SA, Hendersen VW, Brunner RL, Manson JE, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Womens Health Initiative Memory Study: A randomized controlled trial. JAMA 2003;54:2663-72 (Pubitemid 37430137)
14. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Womens Health Initiative Memory Study: A randomized controlled trial. JAMA 2003;289:2651-62. (Pubitemid 37430136)
15. Schmand B, Smit JH, Geerlings MI, Lindeboom J. The effects of intelligence and education on the development of dementia: A test of the brain reserve hypothesis. Psychol Med 1997;27:1337-44. (Pubitemid 27494099)
16. Jellinger KA. Head injury and dementia. Curr Opin Neurol 2004;17:719-23. (Pubitemid 39613004)
17. Martins IJ, Hone E, Foster JK, Sunranilea SI, Gujec A, Fuller SJ, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimers disease and cardiovascular disease. Mol psychiatry 2006;11:721-36. (Pubitemid 44141805)
18. Sidera C, Parsons R, Austen B. The regulation of -secretase by cholesterol and statins in Alzheimers disease. J Neurol Sci 2005;229-30:269-73. (Pubitemid 40341593)
19. Moreira PI, Sautos MS, Seica R, Oliveira CR. Brain mitochondrial dysfunction as a link between Alzheimers disease and diabetes. J Neurol Sci 2007; 257:206-14. (Pubitemid 46856489)
20. Terry RD, Pena C. Experimental production of neurofibrillary pathology: Electron microscopy, phosphate histochemistry and electron probe analysis. J Neuropathol Exp Neurol 1965;24:200-10.
21. Klatzo I, Wisniewski H, Streicher E. Experimental production of neurofibrillary pathology: Light microscopic observations. J Neuropathol Exp Neurol 1965;24:187-99.
22. Alzheimers Association. Alzheimers Disease Facts and Figures-Executive Summary. Chicago, IL, 2009.
23. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimers disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998;51:S2-17.
24. Francis PT, Palmer AM, Snape Ml, Wilcock GK. The cholinergic hypothesis of Alzheimers disease: A review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-47. (Pubitemid 29103513)
25. Braak H, Braak E. Neuropathological staging of Alzheimerrelated changes. Acta Neuropathol 1991;82:239-59.
26. Squire LR, Zola-Morgans S. The medial temporal lobe memory system. Science 1991;253:1380-6. (Pubitemid 21917285)
27. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimers disease: Progress and problems on the road to theurapeutics. Science 2002;297:353-6. (Pubitemid 34790756)
28. Wixted JT. On common ground: Josts (1997) law of forgetting and Ribots (1881) law of retrograde amnesia. Psychol Rev 2004;3:864-79.
29. Yaari R, Corey-Bloom J. Alzheimers disease. Semin Neurol 2007;27:32-41.
30. Yesavage JA, Taylor JL, Kraemer H, Noda A, Friedman L, Tinklenberg JR. Sleep-wake cycle disturbance in Alzheimers disease: How much is due to inherent tract? Int Psychogeriatr 2002;14:73-81. (Pubitemid 34625565)
31. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.
32. McKhann G, Drachman D, Folstein Ml, Katzman R, Price D, Stadlam EM. Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 1984;34:939-44. (Pubitemid 14076461)
33. Hendrie HC, Osuntokun BO, Hall KS, Ogunniyi AO, Hui SL, Unverzagt FW, et al. Prevalence of Alzheimers disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry 1995;152:1485-92.
34. Chan TS, Lam LC, Prince M. Validity and applicability of the Chinese version of Community Screening Instrument for Dementia. Dement Geriat Cogn Disord 2003;15:10-8. (Pubitemid 35404257)
35. Liu SI, Prince M, Chiu MJ, Chen TF, Sun YW, Yip PK. Validity and reliability of a Taiwan Chinese version of the Community Screening Instrument for Dementia. Am J Geriatr Psychiatry 2005;13:581-8.
36. Mirra SS, Hart MN, Terry RD. Making the diagnosis of Alzheimers disease: A primer for practicing pathologists. Arch Pathol Lab Med 1993;117:132-44. (Pubitemid 23057613)
37. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimers Disease (CERAD). Part II: Standardization of the neuropathologic assessment of Alzheimers disease. Neurology 1991;41:479-86.
38. DuBois B, Feldman HH, Jacova C, Dekosky ST, Barberger- Gateau P, Cumming J, et al. Research criteria for the diagnosis of Alzheimers disease: Revising the NINCDSADRDA criteria. Lancet Neurol 2007;6:734-46.
39. Duara R, Lowestein DA, Potter E, Appel J, Greig MT, Urs R, et al. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimers disease. Neurology 2008;71:1986-92.
40. Desikan RS, Cabral HJ, Fischl B, Guttmann CR, Blacker D, Hyman BT, et al. Temporoparietal MR imaging measures of atrophy in subjects with mild cognitive impairment that predict subsequent diagnosis of Alzheimer disease. Am J Neuroradiol 2009;30:532-8.
41. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol 2007;S160- 167. (Pubitemid 351799343)
42. Roberson ED, Mucke L. 100 years and counting: Prospects for defeating Alzheimers disease. Science 2006;314:781-4. (Pubitemid 44706637)
43. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimers disease: Clinical trials and drug development. Lancet Neurol 2010;9:702-16.
44. Haley WE. The family caregivers role in Alzheimers disease. Neurology 1997;48:S25-29. (Pubitemid 27232700)
45. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66. (Pubitemid 32405709)
46. Geldmacher DS. Donepezil for treatment of Alzheimers disease and other dementing conditions. Expert Rev Neurother 2004;4:5-16. (Pubitemid 38082118)
47. Geldmacher DS. Cost-effectiveness of drug therapies for Alzheimers disease. A brief review. Neuropsychiatr Dis Treat 2008;4:549-55. (Pubitemid 352037834)
48. Witt A, Macdonald N, Kirkpatrick P. Memantine hydrochloride. Nat Rev Drug Discov 2004;3:109-10. (Pubitemid 38239767)
49. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Longterm course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22:209-21.
50. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimers disease. The Alzheimers Disease Cooperative Study. N Engl J Med 1997;336:1216-22. (Pubitemid 27183651)
51. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003;289:2819-26. (Pubitemid 37430117)
52. Maillard M, Burnier M. Comparative cardiovascular safety of traditional nonsteriodal anti-infl ammatory drugs. Expert Opin Drug Saf 2006;5:83-94. (Pubitemid 43056441)
53. Orgogozo JM, Gilman S, Dartiques JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after AB42 immunization. Neurology 2003;61:46-54. (Pubitemid 36818745)
54. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat Med 2003;9:448-52 (Pubitemid 36460079)